Jcog0901
WebOncologist, 19:358-366, 2014 [PubMed] Takashima A, Boku N, Kato K, Nakamura K, Mizusawa J, Fukuda H, Shirao K, Shimada Y, Ohtsu A. Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912. http://www.jcog.jp/document/s_0901.pdf
Jcog0901
Did you know?
WebA single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)夽 Haruyasu Murakami … Webscientific article published on 25 January 2014. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
Web27 dic 2024 · Murakami H, Yamamoto N, Shibata T, et al. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer 2014;84:67-72. Web1 set 2024 · A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer …
WebA single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)夽 Haruyasu Murakami a,∗ , Nobuyuki Yamamoto a,b , Taro Shibata c , Koji Takeda d , Yukito Ichinose e , Yuichiro Ohe f , Noboru Yamamoto g , Yuichiro Takeda h , Shinzoh Kudoh i , Shinji Atagi j , Miyako … WebPubMed journal article: A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Download Prime PubMed App to iPhone, iPad, or Android
WebAbstract Objectives We conducted an open-label, multicenter, single-arm study to confirm the efficacy and safety of amrubicin (AMR), a topoisomerase II inhibitor, for treating refractory small-cell lung cancer (SCLC). Patients and methods Patients with chemotherapy-refractory SCLC received 40mg/m2 AMR for 3 consecutive days, every 21 days.
Web14 gen 2011 · 28. 27 offers from $84.00. MOOG 81069 Coil Spring Set. 1,005. 48 offers from $59.07. A-Premium Coil Springs Compatible with Nissan Pathfinder Armada 2004 … bob rappersWebA single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901) (PDF) A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901) Shinzoh Kudoh, Yukito Ichinose, … clip it sandwich boxesWebA single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer, 84:67-72, … clip it serviceWebObjective: A randomized controlled trial to confirm the non-inferiority of laparoscopic surgery to open surgery in terms of overall survival was conducted, and short-term … clip it shock rackWebPlease cite this article in press as: Murakami H, et al. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical … clip its 90sWeb29 apr 2024 · Murakami H, Yamamoto N, Shibata T, et al. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical … bob ratcliffe cricketerWeb1 apr 2014 · Patients and methods. Patients with chemotherapy-refractory SCLC received 40 mg/m 2 AMR for 3 consecutive days, every 21 days. The primary endpoint was the … clip it reading glasses